Bavarian Nordic Initiates Pivotal Phase 3 Trial of PROSTVAC Prostate Cancer Immunotherapy

18-Nov-2011 - Bavarian Nordic A/S announced that its subsidiary, BN ImmunoTherapeutics has initiated the pivotal Phase 3 trial of PROSTVAC® for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The trial is being conducted under a Special Protocol Assessment ...

Bavarian Nordic's Immunotherapy Product Candidate CV-301 Shows Promise in Breast and Ovarian Cancer

14-Nov-2011 - Bavarian Nordic A/S announced that encouraging clinical trial results with CV-301 in patients with metastatic breast or ovarian cancer were published in Clinical Cancer Research. Through an expanded collaboration with the National Cancer Institute (NCI) and license with the National Institutes ...

Bavarian Nordic Obtains Rights to New Cancer Vaccine Product Candidates

11-Oct-2011 - Bavarian Nordic A/S announced that its BN ImmunoTherapeutics subsidiary has entered into an expanded strategic partnership with the National Cancer Institute (NCI). Under the licensing and Cooperative Research and Development Agreements (CRADA), the NCI and Bavarian Nordic will jointly develop ...

Bavarian Nordic awards warrants to board, management and certain employees

02-Sep-2011 - Bavarian Nordic A/S announced that the Board of Directors in Bavarian Nordic has decided to award warrants to management, certain employees in the Company and its subsidiaries and the Board of Directors. The Board decision is made in accordance with the shareholder authorisation for the Board of ...

Bavarian Nordic Enters Into New Research Project to Develop New Cancer Vaccines

10-Mar-2011 - Bavarian Nordic A/S announced that the Company will participate in a new Danish research project, established with the purpose of identifying pathogens (viruses and bacteria) that may cause cancer. The identification of such viruses is an important step towards the development of cancer vaccines. ...

Bavarian Nordic Announces Start of Randomized Phase 2 Study Comparing PROSTVAC and Chemotherapy versus Chemotherapy

02-Mar-2011 - Bavarian Nordic A/S announced the initiation of a new multicenter, randomized Phase 2 study of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with PROSTVAC®. The study will compare PROSTVAC® followed by docetaxel (chemotherapy) versus docetaxel alone.Patients in the ...

Bavarian Nordic Receives NIH Grant to Investigate the Potential of an MVA-BN based Vaccine against Ebola and Marburg Viruses

18-Oct-2010 - Bavarian Nordic A/S announced that the company has received funding from the U.S. National Institutes of Health (NIH) to advance its early research in filoviruses (Ebola and Marburg virus). As previously announced, the company is investigating the potential use of its core vaccine technology, ...

US Government Exercises Next Part of Bavarian Nordic's Freeze-Dried IMVAMUNE Contract

14-Oct-2010 - Bavarian Nordic A/S announced that BARDA (Biomedical Advanced Research and Development Authority) has exercised the next option under the contract for the development of a freeze-dried version of Bavarian Nordic's IMVAMUNE® smallpox vaccine. The option, which was triggered by the successful ...

Bavarian Nordic's MVA-BN patent stands in European validity challenge

07-Oct-2010 - Bavarian Nordic A/S announced that the company successfully defended its core patent covering the MVA-BN® technology despite aggressive attempts from competitors to revoke the patent in Europe. The patent was granted in December 2005 and after the nine month opposition period in which any third ...

Bavarian Nordic Realigns for Expansion

Creation of two business divisions: Cancer Vaccines and Infectious Diseases

05-Oct-2010 - Bavarian Nordic A/S announced the reorganization of the company's primary business areas into two divisions; Cancer Vaccines and Infectious Diseases each led by its own Division President reporting to the President & CEO of the Company. The establishment of two divisions facilitates a stronger ...